Joe Zhou

Joe Zhou

Summary

CAREER PROFILE

20 years experience in the field of Pharmacology, Immunology, Oncology, Pulmonary Diseases, and Cardiovascular Diseases in vivo and in vitro of which 12 years supported US companies.  Major contributor for Repro (Abciximab, GIIb/IIIa and αvβ3 inhibitor).  Major contributor for forwarding two compounds (JNJ-anti-tubulin inhibitor and JNJ-CFMs/FLT3 inhibitor tested on patients in June 2007) into early development.  Research Lead for Centocor two Phase I/II Trial anti-tumor Drugs (CNTO95(Intetumumab) and CNTO328) and independently developed EGFR-targeted Liposome and CNTO 99 (CNTO95 conjugated with doxorubicin liposome) projects.  Professional contributions and recognition includes:

  • Authored 17 papers, 32 abstracts and 35 technical reports.
  • Co-inventor on one issued patent (Anti-angiogenic uses of IL6 antagonists in European Patent (No:03783264.9-2402-US0335651 in European). and awarded five times at JNJ.
  • Participated in establishing oncology team in Centocor.
  • Helped my professor to get two RO1 grants in University of PENN.
  • Cell Sorting License for FACSVantage SE and Cell Flow License from BD, and Molecular Biology and PCR Certificate from New England Biolab.

SELECTED ACCOMPLISHMENTS

In vivo

Extensive experience in PK assays of mice, rats, rabbits, and dogs; Angiogenesis model (Matrigel, corneal, skin model); Tumor xenograft models in mice and rats; Arthritis models (RA, CIA and SCW); Lung acute and chronically inflammatory injuries; Bronchoalveolar lavage; Asthma and EAE models; Flexivent SCIREQ; Human skin transplant; Liver cirrhosis models; Gastric ulcer models; Acute and chronically toxicology; Animal surgery, Injection and dosing of mice, rats, rabbits, dogs and monkeys (IV, IP, SC and PO); Jugular vein cannulation; Cardiac puncture and retro-orbital sinus bleeding.

In vitro

Cell receptor bound assay and receptor internalizatrion; Isolation of neutrophil cells, leukocytes and macrophage; IHC-Immunostaining (tissue fixing, cutting and staining); Cell proliferation and apotosis; Cell cycle assay; Cell migration/invasion /cell adhesion; Tube assay (Matrigel Collagen; Fibrinogen) and rat aorta ring assay; ELISA and RIA; SDS-PAGE Gel; Protein Phosphorylation; Immunoprecipitation and Blot analysis; DNA and RNA separation; PCR and Taqman Quantitative Reverse Transcription-PCR; Gene cloning and expression vector; Antibody preparation, purification and protein labeling with isotopes and fluorescence.

Work History

Work History

Research Associate

·      Evaluating the role of PECAM-1 in angiogenesis and mechanism of lung cancer and inflammatory.

·      Establishing acutely and chronically inflammatory lung injury models.

·      Establishing animal tumor models and angiogenesis model (matrigel and corneal) in vivo.

·      Establishing human skin models in SCID mice for wounding heal, tumor and angiogenesis studies.

·      Helping my professor to get two RO1 Grants (1 million dollars).
Sep 2004 - Present

Scientist

Johnson&Johnson Company

  • Evaluating the effect of anti-IL17 Ab on acute lung diseases in vivo .
  • Evaluating the effect of anti-anti-IL15 Ab on acute lung diseases in vivo .
  • Evaluating the effect of anti-anti-IL13/IL17 DARPIN and RMP on acute lung diseases in vivo .
  • Evaluating the effect of anti-VAP-1 on acute lung diseases in vivo .
  • Establishing the OVA, LPS, aGALCER, HDM the lung disease models.
  • Establishing the lung fibrosis model using systemic administration of Bleomycin..
  • Evaluating the effect of JNJ-MMP 9 Inhibitors on anti-arthritis and anti-asthma in vivo and in vitro.
  • Evaluating the effect of JNJ-CFMS Inhibitors on anti-arthritis in vivo and in vitro.
  • Evaluating the effect of JNJ-CFMS/FLT3 Inhibitors on anti-angiogenesis and anti-tumor in vivo and in vitro.
  • Evaluating the effect of JNJ-Tubulin Inhibitors on anti-angiogenesis and anti-tumor in vivo and in vitro.
  • Screening all new tubulin compounds using cell proliferation, tubulin polymerization assay and cell cycle assay.
  • Evaluating the effect of JNJ-cMet Inhibitors on anti-angiogenesis and anti-tumor.
  • Evaluating the effect of JNJ-PLK1 inhibitors and Onconova PLK1 inhibitor on anti-tumor in vivo and in vitro
  • Evaluating all compound PK and toxicity in mice, rats, and dogs.
  • Major contributor for forwarding two compounds (JNJ-anti-tubulin inhibitor and JNJ-CFMs/FLT3 inhibitor) into early development.
  • Version award in 2005, Encore Award in 2008 and Golden Award for 2009 Science day of JNJ.
Evaluating the effect of anti-IL4/IL13 DARPIN on acute lung diseases in vivo .
Nov 1999 - Aug 2004

Senior Associate Scientist - Scientist

  • Established multiple automated protein- and cell based assays. Developed software for rapid data analysis using Excel.
  • Evaluating the effect of CNTO 328 on anti-angiogenesis and anti-tumor.
  • Evaluating the effect of CNTO 95 on anti-angiogenesis and anti-tumor.
  • Evaluating the effect of anti-uPAR antibodies on anti-angiogenesis and anti-tumor.
  • Evaluating the effect of Reopro (Abciximab, GIIb/IIIa and avb3) on thrombus formation, anti-angiogenesis and anti-tumor.
  • Evaluating the effect of CNTO 95 combination with chemotherapy on tumor cell growth.
  • Evaluating the effect of CNTO 95 conjugated DM1 on anti-angiogenesis and anti-tumor.
  • Evaluating the effect of CNTO 95 Fab conjugated Doxil (CNTO 99) on anti-angiogenesis and anti-tumor.
  • Evaluating the effect of EGF-Phage peptides conjugated Liposome containing Cisplatin on anti-angiogenesis and anti-tumor.
  • Establishing human bone angiogenesis in SCID mice.
  • Twice Star wards and one patent (Anti-angiogenic uses of IL6 antagonists in European).
  • Participated in establishing the oncology department.
Nov 1998 - Nov 1999

Senior Research Associate

3-Dimensional Pharmaceuticals, Inc

·        Screening and Identification of Novel Small Molecule avb3, Urokinase and Metalloprotease Antagonists.

·        Extensive experience in cell based and protein based assays. Developed novel and proprietary assays for the company.

·        The Presidential Award from 3DP in 1999.

Jan 1995 - Jun 1997

Teacher Assistant

·    Studying the Mechanisms of Squalamine (Maginin/Ganeara anti-angiogenic compound that is currently in  AMD clinical trials).

·    Establishing the cell fusion and lipid vesicle fusion methods.

Aug 1989 - Sep 1994

Senior Scientist

Hubei Pharmaceutical Research Institute

·        Screening and evaluating novel small molecular drugs for anti-liver cirrhosis.

·        Establishing the animal models of the liver cirrhosis (Chemical model: Carbon tetrachloride,  acetaminophen and brombenzene; Bile duct model)

·        Evaluating Zu-Jin Tablets and Granule Bismuthic-Kalium Citrate anti-gastric ulcer.

·        Establishing the gastric ulcer models (Chemical, nervous and obstructive model).

·        Evaluating the effect of Aminophylline compounds on asthma.

·        Evaluating the antipyretic, analgesic and anti-inflammatory drugs.

·        Two drugs on market (Zu-Jin Tablets and Granule Bismuthic-Kalium Citrate) in China.

·        Evaluating S99 (Drug purified from Herbs) Anti-atherosclerosis.

Sep 1986 - Aug 1989

Teacher Assistant

Medical College of Wuhan University

·        Establishing the atherosclerosis model using rabbit with high cholesterol diet.

·        Establishing the foam cell model using macrophage with LDL and AcLDL.

·        Purifying proteins (HDL, LDL, apo B, apoA and apo E) and preparing the antibody.

·      The second award of the National Biochemistry Society of China in 1992.

Education

Education
Jan 1994 - Sep 1997

Master

Villanova University
Sep 1986 - Aug 1989

M.S.

Wuhan University
Sep 1981 - Aug 1986

B.S.

Wuhan University

Certifications

Certifications
Nov 2001 - Present

FACS and Cell Sorting

BD